BiotechTube
Pure Greeen Pharmaceuticals

Pure Greeen Pharmaceuticals

Denver, United States· Est.
pgpharma.co
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pure Green Pharmaceuticals is a private, pre-revenue biotech company developing novel, water-soluble sublingual CBD tablets for chronic pain. Its lead programs target diabetic neuropathic pain and osteoarthritic knee pain, with clinical trials underway and regulatory filings initiated in the US. The company leverages a seasoned leadership team with deep expertise in drug development, regulatory affairs, and cannabinoid pharmacology to advance its pipeline through patient-centric, decentralized clinical trials.

Chronic PainDiabetic NeuropathyOsteoarthritis

Technology Platform

Proprietary formulation of water-soluble cannabidiol (CBD) for sublingual delivery via tablets, designed for improved bioavailability and consistent dosing.

Opportunities

The massive and growing global market for chronic pain treatments, particularly for diabetic neuropathy and osteoarthritis, presents a multi-billion dollar opportunity.
Increasing physician and patient acceptance of cannabinoid-based therapies, combined with a clear need for non-opioid alternatives, creates a favorable environment for a clinically validated product.

Risk Factors

Key risks include clinical trial failure, regulatory hurdles specific to cannabis-derived pharmaceuticals, intense competition in the pain therapeutic area, and dependence on raising sufficient capital to fund development through to approval and commercialization.

Competitive Landscape

The company competes in the broad pain management market against opioids, NSAIDs, gabapentinoids, and other analgesics. Within the cannabinoid space, it faces competition from other pharmaceutical developers of synthetic or plant-derived cannabinoids, as well as the unregulated consumer CBD market. Differentiation hinges on its proprietary formulation and prescription-focused clinical data.

More companies in Small Molecule Drugs →More companies in United States →